ADMA Biologics ADMA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $45.33M+68.5% | $49.38M-55.9% | $36.43M+1.4% | $34.22M+6.7% | $26.9M+51.1% | ||
| $1.8M-5.3% | $2M0.0% | $2M+5.3% | $2M+5.3% | $1.9M0.0% | ||
| $6.33M+36.9% | $5.39M-0.8% | $5.05M+58.8% | $4.96M+73.3% | $4.62M+116% | ||
| $3.29M-3.9% | $1.17M+101% | $4.8M— | $1.62M— | $3.43M— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $8M— | -$9K+87.8% | $0+100% | $0+100% | $0+100% | ||
| -$22.57M-146% | $20.76M— | $27.95M+39.6% | $10.31M— | $49.41M+123% | ||
| $15.63M+700% | $9.8M+726% | $5.2M+165% | $19.28M+828% | $1.95M-59.5% | ||
| -$1.23M-968% | —— | —— | $9.27M+599% | $142K-68.2% | ||
| $5.11M+313% | $10.64M+65.6% | -$221K-15.7% | -$2.81M+53.0% | -$2.4M-411% | ||
| $1.6M-38.3% | $547K— | —— | —— | $2.6M+263% | ||
| -$340K+47.7% | -$395K-34.4% | -$234K+81.6% | $0+100% | -$650K-196% | ||
| —— | 0.3%— | —— | —— | —— | ||
| $55K+120% | $51K+104% | $38K+35.7% | $32K-77.5% | $25K-87.0% | ||
| $191K+0.5% | $197K-10.0% | $170K-32.5% | $160K-29.5% | $190K-24.9% | ||
| $58.25M+396% | $35.64M-29.0% | $13.29M-46.9% | $21.14M-53.7% | -$19.68M-787% | ||
| $2.54M-45.9% | $1.08M-60.7% | $14.37M+1,261% | $2.42M+17.2% | $4.7M+100% | ||
| $53K+179% | $192K— | $0-100% | $105K-64.9% | $19K+26.7% | ||
| $2.6M+214% | $1.38M+252% | $1.53M+271% | $1.03M+84.1% | $826K+83.6% | ||
| $2.4M+151% | -$276K+90.0% | -$14.37M-1,209% | -$2.53M-6.8% | -$4.72M-99.8% | ||
| $130.19M— | $8.9M— | —— | —— | $0— | ||
| $588K+482% | $430K+106% | $389K-93.2% | $2.06M+524% | $101K-90.2% | ||
| -$10.13M-42.1% | -$9.12M+70.6% | -$27.83M-9.3% | $0+100% | -$7.13M-393% | ||
| $50.52M+260% | —— | -$28.9M— | —— | -$31.52M-423% | ||
| $1.33M-51.8% | $1.36M-58.1% | $2.76M-22.8% | $2.21M-32.3% | $2.75M+371% | ||
| $91K— | $5.34M+974% | $7.46M+1.5% | $6.89M— | $0— | ||
| $191K+0.5% | $197K-10.0% | $170K-32.5% | $160K-29.5% | $190K-24.9% | ||
| -$36K0.0% | -$36K0.0% | -$36K0.0% | -$35K0.0% | -$36K0.0% | ||
| -$42K— | -$9K+87.8% | $0+100% | $0+100% | $0+100% | ||
| $8M— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | -$2.76M-113% | -$2.76M-113% | -$2.76M-113% | -$2.76M-113% | ||
| -$379K-216% | -$540K-26.8% | -$45K-113% | $426K+147% | -$120K-112% | ||
| $1.6M-38.3% | $547K— | —— | —— | $2.6M+263% | ||
| —— | —— | —— | —— | —— | ||
| $45.33M+68.5% | —— | $36.43M+1.4% | $34.22M+6.7% | $26.9M— | ||
| —— | —— | —— | —— | $400K— | ||
| $53K+179% | $192K— | $0-100% | $105K-64.9% | $19K+26.7% | ||
| $5M— | —— | —— | —— | $0— | ||
| $5.06M-30.0% | $164K-74.5% | $964K-16.8% | $1.19M+71.9% | $7.23M+192% | ||
| —— | —— | —— | —— | —— | ||
| $33.74M-37.2% | $50.35M-7.1% | $58.6M-2.6% | $54.76M+10.1% | $53.71M+25.6% | ||
| $80.75M+32.2% | $88.82M+40.2% | $75.63M+26.8% | $67.23M+17.0% | $61.1M+56.2% | ||
| $57.13M+70.8% | $61.6M+77.4% | $47.52M+29.3% | $40.1M+11.8% | $33.45M+81.8% | ||
| —— | $470.75K— | $470.75K— | $470.75K— | $470.75K— | ||
| $2.1M+6.3% | $1.63M-43.5% | $1.68M-52.1% | $1.83M-51.5% | $1.98M-47.6% | ||
| —— | $775K+14.8% | $775K+14.8% | $775K+14.8% | $775K+14.8% | ||
| -$1.15M+19.8% | -$1.16M+68.0% | -$3.5M-21.0% | -$2.7M+19.4% | -$1.43M+58.2% | ||
| $1.06M-17.4% | $1.13M-11.8% | $1.27M+24.6% | $1.15M+22.3% | $1.29M+28.0% | ||
| $700K— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $523.25K— | $523.25K— | $523.25K— | $523.25K— | ||
| —— | $4.92M— | $4.92M— | $4.92M— | $4.92M— | ||
| $55.71M+329% | $34.56M-27.2% | -$1.08M-104% | $18.72M-57.1% | -$24.38M-434% | ||
| $55.71M+329% | $34.56M-27.2% | -$1.08M-104% | $18.72M-57.1% | -$24.38M-434% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ADMA Biologics generate?
- ADMA Biologics (ADMA) generated $128.3M in operating cash flow over the trailing twelve months.
- What is ADMA Biologics's free cash flow?
- After $20.4M of capital expenditures, ADMA Biologics's free cash flow was $107.9M over the trailing twelve months, up 19.1% year over year.
- Where does ADMA Biologics's cash flow data come from?
- Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
